Skip to main content
PRIMR23 SBER23 Main banner
Icon Legend
Presentation Icons
Pre-Reg Required
Pre-Reg Required
Additional Fee
Additional Fee
Livestreaming Session Icon
Livestreaming Session Icon
Live Session Recorded
Live Session Recorded
On-Demand Session
On-Demand Session
CIP Accredited
CIP Accredited
CPIA Accredited
CPIA Accredited
Call for Session Proposal
Call for Session Proposal
Human Subjects Research
Human Subjects Research
IACUC/Animal Care and Use
IACUC/Animal Care and Use
Crossover
Crossover
Institutional Leadership
Institutional Leadership
Workshop Series
Workshop Series
Thought Leader Series
Thought Leader Series
Deep Dive Series
Deep Dive Series
Learning Lab Series
Learning Lab Series
Networking Series
Networking Series
Vendor Insight Series
Vendor Insight Series
Pillars of PRIM&R Poster Award
Pillars of PRIM&R Poster Award
Poster Icons
Record Session Icon
Record Session Icon
Pre-Reg Required
Pre-Reg Required
Part I/II
Part I/II
CSP Icon
CSP Icon
Livestreaming Session Icon
Livestreaming Session Icon
Prerecorded Session Icon
Prerecorded Session Icon
CIP Accredited
CIP Accredited
Pillars Icon
Pillars Icon
Back
View Video

2023 PRIM&R Annual Conference

A Dialogue With the Feds

FDA Regulated Research

E01 - [IN-PERSON/RECORDED] A Dialogue With FDA

Tuesday, December 5, 2023
4:00 PM – 5:00 PM ET
Location: Ballroom C
Learning Lab Series Human Subjects Research Live Session Recorded CIP Accredited
This session will be offered in-person and recorded for on-demand access by in-person PRIMR23 attendees registered for this day, and PRIMR23/SBER23 Virtual Meeting registrants.

This session will be an open forum led by a panel of FDA representatives, and who will provide brief updates on FDA activities within their Center/Office. The session will then be open for audience questions. Attendees are encouraged to come with questions of interest to all. 

Learning Objectives:

  • Hear from FDA representatives about new and evolving issues, initiatives, regulations, and guidance
  • Ask questions about evolving issues and initiatives at the FDA